US2019054235A1PendingUtilityA1

Optimized bio-synchronous bioactive agent delivery system

57
Assignee: CHRONO THERAPEUTICS INCPriority: Jan 24, 2013Filed: Oct 19, 2018Published: Feb 21, 2019
Est. expiryJan 24, 2033(~6.5 yrs left)· nominal 20-yr term from priority
A61P 9/12A61P 37/08A61P 3/10A61P 25/24A61P 25/22A61P 25/04A61P 25/28A61P 3/04A61P 25/34A61P 25/16A61P 13/02A61P 15/10A61P 15/08A61P 1/08A61M 5/1723G16H 40/63G16H 10/20G16H 20/17A61M 5/30G06F 19/00G06F 19/3468G16Z 99/00G16H 10/60
57
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Optimized bio-synchronous drug delivery begins with establishing a bio-synchronous treatment protocol that incorporates individual temporal and innate biological characteristics into a pharmacological treatment plan. The bio-synchronous treatment protocol is thereafter initiated using bioactive agent delivery device. Bio-synchronous drug delivery includes continual collection of patient data such as physical, psychological, temporal and environmental characteristics. This data is analyzed so to not only determine an initial treatment protocol but to also determining whether modification to the ongoing bio-synchronous treatment protocol is required. And, responsive to determining a modification is required the system modifies the bio-synchronous treatment protocol and use of delivery device. These modifications and treatment protocols can include reactive and proactive psychological support supplied to the patient in a variety of formats.

Claims

exact text as granted — not AI-modified
What is claimed is: 
     
         1 . A treatment system comprising:
 a bio-synchronous delivery device configured to administer a bioactive agent to a patient based on a bio-synchronous treatment protocol;   a user interface adapted to receive patient data; and   an analysis module adapted to receive patient data from the user interface and to provide psychological support to the patient based on the patient data.   
     
     
         2 . The treatment system of  claim 1  wherein a smart phone provides the user interface. 
     
     
         3 . The treatment system of  claim 1  wherein the bio-synchronous delivery device comprises the user interface. 
     
     
         4 . The treatment system of  claim 1  wherein the bio-synchronous delivery device comprises a physiological sensor adapted to collect additional patient data. 
     
     
         5 . The treatment system of  claim 1  wherein patient data includes patient emotional state data. 
     
     
         6 . The treatment system of  claim 5  wherein patient emotional state data includes cravings. 
     
     
         7 . The treatment system of  claim 5  wherein patient emotional state data includes anxiety. 
     
     
         8 . The treatment system of  claim 1  wherein the psychological support includes emotional support. 
     
     
         9 . The treatment system of  claim 1  wherein the analysis module is further adapted to provide emotional support by a text message, supportive tip, vibrating tone, e-mail, call, or voicemail message. 
     
     
         10 . The treatment system of  claim 1  wherein the analysis module is further adapted to modify the bio-synchronous drug delivery protocol. 
     
     
         11 . The treatment system of  claim 1  wherein patient data includes information about compliance with the bio-synchronous drug delivery protocol. 
     
     
         12 . The treatment system of  claim 11  wherein information about compliance with the bio-synchronous drug delivery protocol includes contact of the bio-synchronous delivery device with the patient's skin. 
     
     
         13 . The treatment system of  claim 11  wherein information about compliance with the bio-synchronous drug delivery protocol includes one or more removal of the bio-synchronous delivery device, missing a treatment in the bio-synchronous treatment protocol, or interruption of the bio-synchronous treatment protocol. 
     
     
         14 . The treatment system of  claim 11  wherein information about compliance with the bio-synchronous drug delivery protocol includes time of administration of the bioactive agent, a dosage amount of the bioactive agent, and a time at which dosing ceased. 
     
     
         15 . The treatment system of  claim 1  wherein the bioactive agent is chosen from the group consisting of alprazolam, apomorphine, azelastine, buprenorphine, bupropion, clonidine, enalpril, estradiol, ethinyl estradiol, fentanyl, granisetron, insulin, lidocaine, memantine, methylphenidate, methamphetamine, nitroglycerine, nicotine, norethisterone acetate (NETA), norelgestromine, oxybutynin, pergolide, phenteramine, pramipexole, ramipril, ropinirole, rotigotine, scopolamine, selegiline, tecrine, testosterone, timolol and tolterodine.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.